INO, Inovio Pharmaceuticals, Inc.
** INO reported that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering INO's SynCon(R) universal vaccine related to H1N1 influenza.
The patent granted to the Trustees of The University of Pennsylvania has been licensed exclusively to INO under its existing license agreement with the university. The patent includes claims that cover the synthetic consensus H1 antigen and DNA constructs and vaccines that include this antigen, including universal influenza vaccine INO-3510. This patent also covers methods of treating a patient using the SynCon universal influenza vaccine.
INO researchers have previously shown that its H1N1 influenza SynCon® vaccine provided 100% protection of animals challenged with the 2009 swine origin H1N1 virus and, separately, the H1N1 virus that caused the 1918 Spanish flu that killed over 40 million people. Additional animal studies have also shown that the vaccination generated protective HAI titers against other important H1N1 strains.
The first H1N1 human data from INO's phase I study of VGX-3150, which consists of SynCon constructs against H1N1 and H5N1, is expected in Q2 2012.
INO's INO-3510 is a synthetically created, prophylactic DNA vaccine based on multiple influenza strains within multiple influenza subtypes.
INO is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza.
More about INO at www.inovio.com.
CRWE, Crown Equity Holdings Inc., CRWE.OB
CRWE?s subsidiary Crown Tele Services Inc. is a provider of affordable, world class (VoIP) communications solutions.
Voice over internet protocol provides verbal communication over internet just like common cell phones and landline phones but it is getting very popular because of low cost bills and free of cost calls.
One important concept to understand about VoIP is that unlike public switched telephone network, it is not distance or location dependent.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
CRWE?s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
More about CRWE at www.crownequityholdings.com.
ARNA, Arena Pharmaceuticals, Inc.
** ARNA reported that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >=30) or patients who are overweight (BMI >=27) and have at least one weight-related co-morbid condition. The acceptance of the MAA filing begins the EMA's review process.
In addition, ARNA reported that the FDA has confirmed the scheduling of an Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the lorcaserin New Drug Application (NDA) resubmission on May 10, 2012.
Lorcaserin is a new chemical entity that is believed to act as a selective serotonin 2C receptor agonist. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area believed to be involved in the control of appetite and metabolism.
ARNA has patents that cover lorcaserin in the United States, Europe and other jurisdictions that in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity ARNA might obtain.
ARNA is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.
More about ARNA at www.arenapharm.com
RPTP, Raptor Pharmaceutical Corp.
** RPTP reported that the European Medicines Agency ("EMA") has determined that RPTP's Marketing Authorization Application ("MAA") for its investigational drug candidate, RP103 for the potential treatment of nephropathic cystinosis, submitted earlier this month, is valid. Validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process.
Cystinosis patients have inherited a defective cystine transporter gene which results in body-wide cellular toxicity resulting from the abnormal buildup of the amino acid cystine in the lysosomes.
RP103 is RPTP's proprietary delayed and extended release oral medication to treat the underlying metabolic cause of cystinosis.
RPTP seeks to research, produce, and deliver medicines that improve life for patients with severe, rare disorders.
More about RPTP at www.raptorpharma.com.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.